Portal de Periódicos da CAPES

Treatment recommendations developed by MDS experts of the Polish Adult Leukemia Group (PALG) for management of myelodysplastic syndromes (MDSs) and other MDS-related conditions in Poland for 2021

2022; De Gruyter Open; Volume: 53; Issue: 2 Linguagem: Inglês

10.5603/ahp.a2022.0009

2300-7117

Krzysztof Mądry, Bożena Katarzyna Budziszewska, Karol Lis, Joanna Drozd‐Sokołowska, Bartłomiej Pogłódek, Rafał Machowicz, Edyta Subocz, Katarzyna Wiśniewska‐Piąty, Tomasz Wróbel, Jan Maciej Zaucha, Ewa Zarzycka, Ewa Karakulska‐Prystupiuk, Lidia Gil, Aleksandra Butrym, Agnieszka Tomaszewska, Grzegorz Basak, Anna Waszczuk‐Gajda, Agnieszka Pluta, Paweł Szwedyk, Małgorzata Jarmuż‐Szymczak, Jagoda Rytel, Jadwiga Dwilewicz‐Trojaczek,

Acute Lymphoblastic Leukemia research

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell disorders that are characterized by ineffective blood cell production and a variable risk of transformation into acute myeloid leukemia. In recent years, significant progress in MDS biological research has allowed the addition of new drugs to the few existing therapeutic options. This article presents the recommendations of MDS experts of the Polish Adult Leukemia Group for the treatment of myelodysplastic syndromes, and for the management of conditions that are particularly common in patients with MDS i.e. infections, iron overload, and disease recurrence after hematopoietic cell transplantation. The aim of this study was to present a clear therapeutic algorithm to facilitate decision-making in everyday practice.